References
- Carcamo, W. C., M. Satoh, H. Kasahara, et al. 2000. Induction of cytoplasmic RR structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells. PLoS One 6: e29690
- Stinton, L. M., R. P. Myers, C. S. Coffin, and M. J. Fritzler. 2013. Clinical associations and potential novel antigenic targets of autoantibodies directed against RR in chronic hepatitis C infection. BMC Gastroenterol. 13: 50
- Probst, C., C. Radzimski, I. M. Blöcker, et al. 2013. Development of a recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies against “rings and rods”-associated inosine 5’-monophosphate dehydrogenase 2 in viral hepatitis C. Clin. Chim. Acta 418: 91–96
- Keppeke, G. D., E. Nunes, M. L. G. Gomes Ferraz, et al. 2012. Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α. PLoS One 7: e45392
- Carcamo, W. C., A. Ceribelli, S. J. Calise, et al. (2013). Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients. J. Clin. Immunol. 33: 420–426
- Novembrino, C., A. Aghemo, C. Ferraris Fusarini, et al. (2014). Interferon–ribavirin therapy induces serum antibodies determining ‘rods and rings’ pattern in hepatitis C patients. J. Viral Hepat. 21: 944–949
- Kamath, P. S., R. H. Wiesner, M. Malinchoc, et al. 2001. A model to predict survival in patients with end-stage liver disease. Hepatology 33: 464–470
- Guido, M., A. Mangia, and G. Faa. 2011. Chronic viral hepatitis: the histology report. Dig. Liver Dis. 43S: S331–S343
- Covini, G., W. C. Carcamo, E. Bredi, et al. (2012). Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Antivir. Ther. 17: 805–811
- Seeling, H. P., H. Appelhans, O. Bauer, et al. 2011. Autoantibodies against inosine-5′-monophosphate dehydrogenase 2—characteristics and prevalence in patients with HCV-infection. Clin. Lab. 57: 753–765
- Shaikh, Y., A. Krantz, and Y. El-Farra. 2013. Anti-rods and rings autoantibodies can occur in the hepatitis c-naïve population. J. Prev. Hyg. 54: 175–180
- Carvalho, P. L., W. de Melo, A. Dellavanceet al. 2014. IV Brazilian guidelines for autoantibodies on HEp-2 cells. Rev. Bras. Reumatol. 54: 44–50
- Juda, P., J. Šmigová, L. Kováčik, et al. 2014. Ultrastructure of cytoplasmic and nuclear inosine-5′-monophosphate dehydrogenase 2 “rods and rings” inclusions. J. Histochem. Cytochem. 62: 739–750
- Allisona, A. C., and E. M. Euguia. 2000. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47: 85–118
- Chan, E. S., and B.N. Cronstein. 2002. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 4: 266–273
- Keppeke, G. D., M. Satoh, M. L. Ferraz, et al. 2014. Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α. Immunol. Res. 60: 38–49
- Morales, J. M., N. Kamar, and L. Rostaing. 2012. Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy. Contrib. Nephrol. 176: 10–23
- Rauch, A., Z. Kutalik, P. Descombes, et al. 2010. Genetic variation in IL28B is associated with chronic Hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138: 1338–1345
- Ghany, M. G., D. R. Nelson, D. B. Strader, et al. 2011. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: 1433–1444
- Feeney, E. R., and R. T. Chung. 2014. Antiviral treatment of hepatitis C. BMJ 349: g3308
- Liu, C. H., C. C. Liang, C. J. Liu, et al. 2012. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Antivir. Ther. 17: 477–484